In line with these findings, a study involving renal cell carcinoma patients receiving PD-1 pathway blockade monotherapy or combination therapy with CTLA-4 blockade showed that tumors with loss of function mutations in Pbrm1 correlated with clinical benefits from the treatment (74). This evidence concerns the gene PDCD1 and renal cell carcinoma.